Keep up-to-date with the latest news from the HTA, find out about events that we are running and subscribe to our e-newsletter. Use the filter options on the right hand side in order to find news articles by date, tags or audience. Older news stories can be found on previous versions of this site, held on the national archives.
The European Commission is consulting on the EU legislation on blood, tissues and cells.
The HTA’s Triennial Review The HTA’s triennial review was conducted by the Cabinet Office to provide assurance to the Department of Health and the public that the HTA’s functions are still required and that we are operating efficiently.
We are aware of a situation in the North East of England where a number of items of human tissue, retained for criminal justice and coronial purposes over the course of the last 20 years, have been kept for longer than was necessary.
The Human Tissue Authority (HTA) was surprised to be named as the respondent in the matter of SW earlier this year – there had been no contact or information from the applicants before the papers were served – on a matter relating to a bone marrow donation involving an individual who it was claim
The HTA has published its annual Business Plan for 2017/18 and a refreshed version of our three-year Strategy.
Today we have launched our updated Codes of Practice and Standards, which are available on our website here. These provide practical guidance on human tissue legislation for prof
We have been hosting a series of webinars in February and March, to talk about our revised Codes of Practice and Standards, which launch in April.
Consultation on two new EU Directives - the application of a Single European Code and the Import of Tissues and Cells
The Department of Health is consulting on draft Human Tissue (Quality and Safety for Human Application) (Amendment) Regulations 2017.
Today the Human Tissue Authority (HTA) has announced annual licence fees for 2017/18.
Working in an increasingly innovative environment, regulatory authorities must balance their essential roles in protecting public health with making sure new, innovative treatments are made available to the UK healthcare sector at the earliest, safest opportunity.